Acute Graft Versus Host Disease
Conditions
Keywords
acute GVHD, MTX, Corticosteroid
Brief summary
The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid treatment for grade III-IV acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Detailed description
Allo-HSCT is an effective treatment of malignant hematopoietic diseases. However, aGVHD remains a major complication after allo-HSCT and the destruction of recipient tissues by alloantigen-activated T cells is a key event in the development of aGVHD. Corticosteroid is the standard first-line therapy for aGVHD due to their roles in suppressing T cell responses. However, the response rate of corticosteroid was approximate 50%, and the clinical outcomes of patients with corticosteroid refractory GVHD were poor. Thus far, no combination therapy had been prove to be superior to corticosteroid alone as initial therapy for aGVHD. The study hypothesis: MTX combined corticosteroid treatment could help to further ameliorate the activity of T cells and control aGVHD.
Interventions
DRUGMethotrexate
Methylprednisolone 2 mg/kg/day MTX (5-10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II
Sponsors
Peking University People's Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Patients who are fully informed and sign informed consent by themselves or their guardians; 2. Patients receiving allogeneic hematopoietic stem cell transplantation; 3. Patients with acute graft-versus-host disease of grade III-IV were diagnosed after transplantation; 4. Patients with stable implantation of granulocytes and platelets.
Exclusion criteria
1. Patients who have received more than one transplant; 2. Patients with overlap syndrome; 3. Patients within six months after the failure of the first transplantation; 4. Patients with uncontrollable active infection; 5. Patients with recurrence of primary malignant hematopathy; 6. Patients with donor lymphocyte infusion induced graft-versus-host disease after first intervention; 7. Patients with serious respiratory diseases; 8. Patients with severe renal insufficiency; 9. Patients with serious and uncontrolled heart disease; 10. Patients with severe hepatobiliary diseases unrelated to graft-versus host disease; 11. Within one week patients who need to use more than 1mg/kg/d methylprednisolone for reasons other than graft-versus-host disease; 12. patients who have participated in other clinical trials within 1 month; 13. The researcher judges that there are other factors that are not suitable for participating
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate (ORR) for GVHD treatment after treatment | 14 days | Overall response rate is defined as the proportion of patients demonstrating a complete response or partial response without requirement for additional systemic therapies for an earlier progression, mixed response or non-response |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate (ORR) at 28 days after treatment | 28 days | Overall response rate is defined as the proportion of patients demonstrating a complete response or partial response without requirement for additional systemic therapies for an earlier progression, mixed response or non-response |
| relapse rate | 1 year | Relapse rate is defined as the proportion of patients demonstrating a morphological relapse of the original malignant hematological disease |
| Non-relapse mortality | 1 year | Non-relapse mortality |
| Overall survival | 1 year | Overall survival |
| Disease free survival | 1 year | Disease free survival |
| Failure free survival | 1 year | Failure free survival |
| Chronic GVHD | 1 year | number of participants with chronic GVHD at one year |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety data (side effect) | 1 year | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.Data collection including questionnaires at individual and group visits and physician interviews at individual visits will be used to assess participants for treatment-related adverse events. |
Countries
China
Contacts
Primary ContactYu Wang, Dr.
Outcome results
None listed